DR. JAMES P MCCARRON, MD
Urology at Park Ave, New York, NY
License number
New York 1121731
Category
Radiology
Type
Urology
Address
Address
820 Park Ave, New York, NY 10021
Phone
(212) 861-3000
(212) 861-3424 (Fax)
(212) 861-3424 (Fax)
Personal information
See more information about JAMES P MCCARRON at radaris.comName
Address
Phone
39 Riverside Pl, Dobbs Ferry, NY 10522
3450 Edgerton Ave, Wantagh, NY 11793
815 Park Ave APT 5C, New York, NY 10021
502 Treadlemire Rd, Berne, NY 12023
25 Floral Rd, Cortlandt Mnr, NY 10567
Organization information
See more information about JAMES P MCCARRON at bizstanding.comJames P McCarron MD
820 Park Ave, New York, NY 10021
Industry:
Medical Doctor's Office, Urologist
Doing business as:
James P Mccarron
Phone:
(212) 861-3000 (Phone)
Insurance/Billing Supervisors:
James P. Mccarren (Owner, Urology, Medical Doctor),Margie Colon (Insurance/Billing Supervisor)
Professional information
Owner, Animation Control
Position:
Owner at Animation Control
Location:
Greater New York City Area
Industry:
Animation
Work:
Animation Control
since Sep 1994
-
Owner
Education:
School of Visual Arts
Bachelor of Fine Arts, Illustration / Filmaking
Bachelor of Fine Arts, Illustration / Filmaking
Dr. James P Mccarron, New York NY - MD (Doctor of Medicine)
Specialties:
Urology
Address:
James P Mccarron MD
820 Park Ave, New York 10021
(212) 861-3000 (Phone)
820 Park Ave, New York 10021
(212) 861-3000 (Phone)
Certifications:
Urology, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
James P Mccarron MD
820 Park Ave, New York 10021
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
820 Park Ave, New York 10021
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
Education:
Medical School
University of Virginia / Main Campus
Graduated: 1968
U Mich Hosp
New York Hosp
University of Virginia / Main Campus
Graduated: 1968
U Mich Hosp
New York Hosp
Teacher At Somerset Hills Boe
Position:
Teacher at Somerset Hills BOE, Art Teacher at Somerset Hills BOE
Location:
Greater New York City Area
Industry:
Fine Art
Work:
Somerset Hills BOE
since Sep 1992
-
Teacher
Somerset Hills BOE
- Bedwell School since Sep 1992
-
Art Teacher
Education:
Kean University 2006 - 2008
MA Art Education Kean University 1986 - 1991
BA Art Education
MA Art Education Kean University 1986 - 1991
BA Art Education
James Patrick McCarron, New York NY
Specialties:
Urologist
Address:
525 E 68Th St, New York, NY 10065
820 Park Ave, New York, NY 10021
820 Park Ave, New York, NY 10021
Education:
University of Virginia, School of Medicine - Doctor of Medicine
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Urology
University of Michigan Health System - Residency - Surgery
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Urology
University of Michigan Health System - Residency - Surgery
Board certifications:
American Board of Urology Certification in Urology
Owner, Medicalpractice
Position:
Owner at medicalpractice
Location:
Greater New York City Area
Industry:
Medical Practice
Work:
medicalpractice
-
Owner
Methods Of Treating An Inflammatory-Related Disease
US Patent:
2005015, Jul 14, 2005
Filed:
Jan 12, 2004
Appl. No.:
10/754547
Inventors:
Longgui Wang - Flushing NY, US
Xiao Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon Mencher - New York NY, US
James McCarron - New York NY, US
Xiao Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon Mencher - New York NY, US
James McCarron - New York NY, US
International Classification:
A61K031/404
US Classification:
514414000
Abstract:
The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
Methods Of Treating An Inflammatory-Related Disease
US Patent:
2005019, Sep 8, 2005
Filed:
Apr 13, 2005
Appl. No.:
11/104422
Inventors:
Longgui Wang - Flushing NY, US
Xiao Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon Mencher - New York NY, US
James McCarron - New York NY, US
Xiao Liu - Flushing NY, US
Lian Mo - Palo Alto CA, US
Simon Mencher - New York NY, US
James McCarron - New York NY, US
International Classification:
A61K038/13, A61K031/7056, A61K031/404
US Classification:
514414000, 514023000, 514011000, 514406000, 514171000, 514570000, 514159000
Abstract:
The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
Method Of Treating Androgen Independent Prostate Cancer
US Patent:
2010009, Apr 22, 2010
Filed:
Sep 16, 2009
Appl. No.:
12/561180
Inventors:
Longgui Wang - Flushing NY, US
Simon K. Mencher - New York NY, US
James P. McCarron - New York NY, US
Simon K. Mencher - New York NY, US
James P. McCarron - New York NY, US
International Classification:
A61K 39/395, A61K 31/404, A61P 35/04, A61K 31/573, A61K 38/00
US Classification:
4241411, 514414, 514171, 514 12
Abstract:
The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.